Home  »  Industry   »  Cytokinetics Incorporated (CYTK) Quarterly Perform...

Cytokinetics Incorporated (CYTK) Quarterly Performance is 6.16%: Here is the Surprise Factor

At the end of the latest market close, Cytokinetics Incorporated (CYTK) was valued at $41.11. In that particular session, Stock kicked-off at the price of $40.95 while reaching the peak value of $43.13 and lowest value recorded on the day was $39.881. The stock current value is $42.39.Recently in News on August 1, 2022, Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4). Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on July 29, 2022 it granted stock options to purchase an aggregate of 88,200 shares of common stock to 11 new employees, whose employment commenced in July 2022, as a material inducement to their employment. You can read further details here

Cytokinetics Incorporated had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $49.41 on 06/28/22, with the lowest value was $29.26 for the same time period, recorded on 01/24/22.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


Cytokinetics Incorporated (CYTK) full year performance was 47.34%

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Cytokinetics Incorporated shares are logging -14.21% during the 52-week period from high price, and 52.43% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $27.81 and $49.41.

The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 3058139 for the day, which was evidently higher, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Cytokinetics Incorporated (CYTK) recorded performance in the market was -7.00%, having the revenues showcasing 6.16% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 3.97B, as it employees total of 253 workers.

The Analysts eye on Cytokinetics Incorporated (CYTK)

During the last month, 10 analysts gave the Cytokinetics Incorporated a BUY rating, 1 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 40.05, with a change in the price was noted +4.26. In a similar fashion, Cytokinetics Incorporated posted a movement of +11.17% for the period of last 100 days, recording 1,144,834 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for CYTK is recording 1.70 at the time of this writing. In addition, long term Debt to Equity ratio is set at 1.69.

Technical rundown of Cytokinetics Incorporated (CYTK)

Raw Stochastic average of Cytokinetics Incorporated in the period of last 50 days is set at 41.06%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 43.08%. In the last 20 days, the company’s Stochastic %K was 38.53% and its Stochastic %D was recorded 39.70%.

Considering, the past performance of Cytokinetics Incorporated, multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -7.00%. Additionally, trading for the stock in the period of the last six months notably improved by 27.72%, alongside a boost of 47.34% for the period of the last 12 months. The shares increased approximately by 7.40% in the 7-day charts and went up by 3.39% in the period of the last 30 days. Common stock shares were driven by 6.16% during last recorded quarter.

Leave a Comment

Your email address will not be published.

On Key

Related Posts